The Biology of Estrogen Receptor-Negative Breast Cancer in Various Racial and Ethnic Groups (U01)

Post Date

August 13th 2009

Application Due Date

January 5th 2010

Funding Opportunity Number

RFA-CA-09-026

CFDA Number(s)

93.396

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Regional Organizations; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $2000000

• Award Range:

  $None - $667000

Grant Description

Purpose.The purpose of this funding opportunity announcement (FOA) is to promote the systematic study of the biology of estrogen receptor (ER)-negative human breast cancers, the characterization of their molecular features, the signaling pathways and networks that support their growth, as well as to identify differences in the biology of ER-negative breast tumors among racial and ethnic groups. The information will be crucial in developing early detection and intervention strategies. This initiative will support studies on: the basic biology of ER-negative breast cancers and delineation of differences that exist between ER-positive and ER-negative breast cancers; the identification of the subtypes or heterogeneity that exist within ER-negative breast cancers; and the determination of whether the biology of ER-negative breast tumors differs across racial and ethnic groups. In order to address these goals, the National Cancer Institute (NCI) solicits applications from collaborative teams of interdisciplinary investigators focused on characterizing the biologic drivers, including genetic, epigenetic, molecular, and cellular factors, of ER-negative human breast cancer development and progression. Mechanism of Support. This FOA will utilize the NIH U01 cooperative agreement mechanism. Funds Available and Anticipated Number of Awards. The NCI expects to commit approximately $10 million for 5 years to fund up to three awards.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-09-026.html